Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

Sponsor
The University of Texas Health Science Center at San Antonio (Other)
Overall Status
Completed
CT.gov ID
NCT00223483
Collaborator
US Department of Veterans Affairs (U.S. Fed)
512
2
196.4
256
1.3

Study Details

Study Description

Brief Summary

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Isolation of genomic DNA

Detailed Description

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

Study Design

Study Type:
Observational
Actual Enrollment :
512 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Study Start Date :
Mar 1, 2005
Actual Primary Completion Date :
Dec 11, 2020
Actual Study Completion Date :
Jul 14, 2021

Outcome Measures

Primary Outcome Measures

  1. Repository collection of plasma and serum for future analysis. [12 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Must be able to give blood

  • Must be able to give informed consent

  • Signed, written informed consent

Exclusion Criteria:
  • Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.

  • Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division San Antonio Texas United States 78229
2 The University of Texas Health Science Center at San Antonio San Antonio Texas United States 78229

Sponsors and Collaborators

  • The University of Texas Health Science Center at San Antonio
  • US Department of Veterans Affairs

Investigators

  • Study Director: Cesar O Freytes, MD, The University of Texas Health Science Center at San Antonio

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00223483
Other Study ID Numbers:
  • HSC20040268H
First Posted:
Sep 22, 2005
Last Update Posted:
Jul 16, 2021
Last Verified:
Jul 1, 2021
Keywords provided by The University of Texas Health Science Center at San Antonio
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2021